PO.CL01.02 · 临床研究
评估多重数字PCR中的光谱重叠与串扰,以有效监测癌症临床试验中的下一代CAR T细胞
Assessment of spectral overlap and crosstalk in multiplex digital PCR for effective monitoring of next-generation CAR T-cells in cancer clinical trials
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:随着新型嵌合抗原受体(CAR)T细胞作为二线疗法用于已接受过某种获批CAR治疗的患者,针对下一代构建体的临床试验研究需要监测残留的第一代CAR-T疗法的存在情况,而这往往只能依靠有限的患者样本。多重数字PCR(dPCR)无需标准曲线即可实现绝对定量,并支持检测低至10个拷贝,是在有限的临床试验标本中监测多种获批CAR-T的理想方法(Morley,2014;QIAGEN,无日期)。虽然多重检测提高了效率,但也带来了诸如光谱重叠等挑战,可能造成串扰和误读。在此,我们研究了信号渗漏如何影响多重dPCR中的信号解读,并评估了阈值调整和软件更新在减轻串扰、保持QIAcuity平台上多种CAR-T监测准确性方面的有效性。
方法:使用标记有FAM、TxRED、VIC、TAMRA和Cy5的探针,在五个光学通道中检测了一种靶向三个CAR结构域、一个病毒安全标志物和一个参照基因的多重dPCR检测。在QIAcuity上运行了两种形式:单重反应以确认特异性和基线串扰,以及多重反应以评估累积干扰。使用Software Suite(SS)2.5和3.1版本进行分析。荧光图评估了信号清晰度、串扰以及光学和阈值设置对液滴分类和定量的影响。
结果:单重反应显示FAM、VIC、TAMRA或Cy5通道无信号渗漏。TxRED渗漏至Cy5。TxRED渗漏至Cy5,TAMRA渗漏至VIC,这一点通过二维图得到证实,图中显示了双阳性模式以及仅含TAMRA样本中出现的意外VIC阳性液滴。VIC至TAMRA的串扰呈浓度依赖性,在较低输入水平下减弱,而TxRED至Cy5的串扰则保持恒定。通过光学或阈值调整,TAMRA的信号清晰度得到改善。尽管存在可见的信号渗漏,多重定量仍保持准确。Cy5标记的靶标被正确识别,软件忽略了TxRED的信号渗漏。SS 2.5和3.1版本之间在串扰或定量准确性方面未观察到差异,证实了各版本更新之间的一致性。
结论:光谱信号渗漏,尤其是TxRED渗漏至Cy5,是信号误分类的主要来源。两个软件版本中的手动阈值设定和光学调整均有效减少了串扰,改善了所有CAR结构域的定量。这些发现凸显了优化检测设计和分析工具对于可靠定量残留CAR-T疗法的重要性,而这对于下一代CAR-T疗法的安全推进至关重要。
查看英文原文 English abstract
Introduction: As new chimeric antigen receptor (CAR) T cells emerge as secondary therapies in patients already treated with an approved CAR, clinical trial investigation of next generation constructs requires monitoring for the presence of residual first generation CAR-T therapies, often from limited patient samples. Multiplex digital PCR (dPCR) enabling absolute quantification without standard curves and supporting detection of as few as 10 copies, is an ideal approach to monitor multiple approved CAR-Ts in a limited clinical trial specimen (Morley, 2014; QIAGEN, n.d.). While multiplexing improves efficiency, it introduces challenges such as spectral overlap, potentially causing crosstalk and misinterpretation. Herein, we investigate how bleed-through affects signal interpretation in multiplex dPCR and evaluate the effectiveness of threshold adjustments and software updates in mitigating crosstalk and preserving monitoring accuracy of multiple CAR-Ts on the QIAcuity platform.
Method: A multiplexed dPCR assay targeting three CAR domains, a viral safety marker, and one reference gene was tested using probes labeled with FAM, TxRED, VIC, TAMRA, and Cy5 across five optical channels. Two formats were run on QIAcuity: singleplex reactions to confirm specificity and baseline crosstalk, and multiplexed reactions to assess cumulative interference. Analysis was performed using Software Suite (SS) versions 2.5 and 3.1. Fluorescence plots assessed signal clarity, crosstalk, and the impact of optical and threshold settings on droplet classification and quantification.
Result : Singleplex reactions showed no bleed-through in FAM, VIC, TAMRA, or Cy5 channels. TxRed bled into Cy5. TxRED bled into Cy5, and TAMRA into VIC, confirmed by 2D plots showing double-positive patterns and unexpected VIC-positive droplets in TAMRA-only samples. VIC-to-TAMRA crosstalk was concentration-dependent, decreasing at lower input levels, while TxRED-to-Cy5 remained constant. Signal clarity for TAMRA improved with optical or threshold adjustments. Despite visible bleed-through, multiplex quantification remained accurate. Cy5-labed targets were correctly identified, with software ignoring TxRED bleed-through. No differences in crosstalk or quantification accuracy were observed between SS versions 2.5 and 3.1, confirming consistency across updates.
Conclusion: Spectral bleed-through, especially from TxRED into Cy5, was a key source of signal misclassification. Manual thresholding and optical adjustments in both software versions effectively reduced crosstalk and improved quantification of all CAR domains. These findings highlight the importance of optimized assay design and analysis tools for reliable quantification of residual CAR-T therapies, which are critical for safe advancement of next generation CAR-T therapies.
利益披露 Disclosure
S. Johnson, None..
Y. Raj, None..
N. Riccitelli, None.